Vaxcyte shares jump after late-stage vaccine trial results
Vaxcyte stock surged after late-stage results suggested its lead vaccine candidate could steal significant share from Pfizer and Merck in a multi-billion-dollar market.
Vaxcyte shares surged Monday after late-stage trial results indicated its lead vaccine candidate could capture significant share from Pfizer and Merck in a multi-billion-dollar market. The company’s pipeline candidate, VAX-31, targets 31 strains of the bacteria responsible for pneumonia.